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ABSTRACT
Electrochemical oxidation is a common method for the degradation of chemicals
by applying potential at a definite value. In this research, ‘cyclic voltammetry’ experiments
were conducted to find out the oxidation potential for 8 different pharmaceuticals. Mainly,
3 different pH solutions (pH 6.0, 7.5, 9.0) and 9 different concentrations (1, 2, 5, 10, 20,
50, 100, 200, 500 µM) were studied for each of the pharmaceuticals in this experiments.
Acetaminophen, Ibuprofen, Naproxen Sodium, Caffeine showed oxidation peak at 0.340.79V, 1.37- 1.39V, 0.94-1.01V, 1.44-1.55V respectively at different pH and
concentrations. Antibiotic and antihistamine pharmaceuticals i.e. Erythromycin Hydrate,
Triclosan, Sulfanilamide, Diphenhydramine Hydrochloride showed oxidation peak at 0.911.19V, 0.58-1.03V, 0.86-1.11V, 0.79-1.22V respectively at different pH and
concentrations. The oxidation potential varies with both pH and concentration for every
pharmaceutical. The chronoamperometry experiments were performed to determine the
relationship between the concentration of the pharmaceuticals and the current. The sensor
curves have been developed from the data of the chronoamperometry experiments. To
observe the electrochemical degradation, the potential (higher than the oxidation potential
found by the cyclic voltammetry experiments) have been applied to the pharmaceutical
iv

solutions and samples were collected at different time from the solutions during the period
of applying potential. The samples were then analyzed in HPLC instrument. Triclosan and
Sulfanilamide have shown successful degradation. The 1st order reaction constants are
0.0039 min-1 and 0.0148 min-1 for the degradation of sulfanilamide and Triclosan
respectively.
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CHAPTER 1 INTRODUCTION

Pharmaceuticals are so much widely used worldwide that these can be found in
terrestrial and aquatic system in considerable amount [1]–[5]. This amount is still
increasing slowly, but continuously [6], [7]. The presence of the pharmaceuticals or their
derivatives can cause adverse effects on aquatic lives, plants and even on humans [6], [8].
Since we cannot avoid medication, thus it is now a concern to reduce the concentration of
the pharmaceuticals from environment. Different approaches were discovered over the
years to degrade the pharmaceuticals from the wastewater. In this work, electrooxidation
method have been applied to degrade and remove the pharmaceuticals.

1.1. What is CEC

CEC stands for ‘Contaminants of Emerging Concern’. Pharmaceuticals are now found
in such a considerable amount in natural water sources that these are now being considered
as CEC. CEC also includes some other types of chemicals and materials which can have
negative effect on the animal being or on environment. CEC includes pesticides, industrial
effluents, pharmaceuticals, personal care products etc. Most of these compounds reach the
environment through municipal wastewater treatment plant where these compounds are not
being removed completely [5]. That is why scientists are now researching on how to
remove or degrade those CEC compounds from municipal wastewater. Since, CEC is a
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broad area of compounds, in my research I concentrated on the degradation of few of the
pharmaceuticals which are commonly used in urban area.

1.2. Background

The consumption of pharmaceuticals is increasing with time. One report showed that
the antibiotic consumption was increased by an average of 36% in 71 countries and even
it was as high as 76% for few other countries during the period of 2000 to 2010 [9].

Pharmaceuticals can enter the environment by different pathways such as excretion and
metabolism [10], unused or expired medicine thrown as solid waste, discharge of treated
wastewater, seepage from sewer lines, landfills and septic systems etc. In general,
pharmaceuticals are metabolized in the body by different mechanisms such as oxidation,
reduction, conjugation, hydrolysis etc. and transformed into more polar and water soluble
derivatives which have a reduced pharmacological activity compared to the original
compound [11]. The pharmaceuticals or other chemical compounds which are detected at
low levels in surface water are called as Contaminants of emerging concern (CEC) which
may also act as endocrine disruptors (EDCs). The presence of CECs can be detected by
High Performance Liquid Chromatography (HPLC), Mass Spectrometry, Isotope-Dilution
Mass Spectrometry (ISTD) etc. Generally, CECs concentration in wastewater is found to
be in the range between ppt (ng L-1) to ppm (mg L-1).
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The veterinary pharmaceuticals can enter the surface water [12], [13]. The
concentration of different pharmaceuticals in several countries have been shown in
previous studies [6]. Different anti-inflammatories and analgesics i.e. diclofenac, ibuprofen
etc. have been found in groundwater and aquifers in Germany, England and Spain [14]–
[17]. Caffeine was also found in the wastewater, sewage effluent, groundwater and surface
water [18], [19].

The presence of the pharmaceuticals in water system can bio-accumulate within the
food chain and affect aquatic lives as well as human health in long term. This can hinder
normal function of hormones and thus can have reproductive effects in aquatic organisms
[20]. These can be reactive to non-target organisms [3], [21]–[23]. Different researches
showed the negative impact of the pharmaceuticals on the reproduction of aquatic lives and
the growth of algae and phytoplankton [24], [25]. The presence of antibiotic
pharmaceuticals can promote the antibiotic resistance in bacteria which can be detrimental
for human and animals [25]–[27]. The long time exposure of the pharmaceuticals in water
can impair health condition of fish such as kidney, grill disease etc. [3], [8], [28], [29].
Some pharmaceuticals like Carbamazepine does not generally undergo to the degradation
or adsorption process and thus can be found in groundwater or surface water in higher
concentration [30]. For these reasons, this is now very important to successfully degrade
the pharmaceuticals as well as CEC into harmless compound.
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1.3. Type of Pharmaceuticals used

Different kinds of pharmaceuticals are found in the aqueous environment such as
analgesics,

antibiotics,

anti-inflammatories,

steroids,

antipyretics,

stimulants,

antihistamines etc. [6], [8], [31]. In this work, 8 pharmaceuticals from 4 different categories
have been used to study. The list of pharmaceuticals along with their categories are shown
below.
Category-1: Analgesic and Anti-inflammatory Drugs
i.

Acetaminophen

ii.

Ibuprofen

iii.

Naproxen Sodium

Categoory-2: Central Nervous System (CNS) Stimulant Drugs
i.

Caffeine

Category-3: Antibiotic Drugs
i.

Erythromycin Hydrate

ii.

Triclosan

iii.

Sulfanilamide

Category-4: Antihistamine Drugs
i.

Diphenhydramine Hydrochloride

4

Acetaminophen [IUPAC name: N-(4-hydroxyphenyl)acetamide] is the prescription
and non-prescription analgesic and antipyretic drug which is widely used to reduce fever
and pain. Acetaminophen is non-carcinogenic and prescribed for the patients who cannot
tolerate aspirin [32]. Ibuprofen (Ibu) [IUPAC name: 2-[4-(2-methyl propyl) phenyl] propanoic
acid] is a non-prescription, non-steroidal anti-inflammatory drug (NSAID) used for treating

arthritis, fever, pain and inflammation [33]. Naproxen sodium [IUPAC name: sodium;(2S)2-(6-methoxynaphthalen-2-yl)propanoate] is the sodium salt form of naproxen which is
non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory analgesic and
antipyretic properties. It is used to moderate pain relief and in the treatment of arthritis,
other rheumatic or musculoskeletal disorders etc. [34]. This is both prescription and nonprescription drug.

CNS stimulant drugs e.g. Caffeine, Modafinil etc. are generally used to treat
excessive sleepiness and restore alertness. Caffeine [IUPAC name: 1,3,7-trimethylpurine2,6-dione] is the world’s most widely consumed psychoactive substance [35]. It is present
in cocoa, tea, chocolate, soft and energy drinks, coffee and certain medicines. Caffeine's
pharmacological usage is to increase alertness, produce agitation, relax smooth muscle and
stimulate diuresis and cardiac muscle etc. It was found also to be useful in the treatment of
some types of headache [36].

Antibiotics are used to treat bacterial infections. Erythromycin Hydrate
(C37H69NO14) or Erythromycin is a prescribed drug used for the treatment of mouth
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infections, skin infections, urine infections, respiratory infections etc. Triclosan [IUPAC
name: 5-chloro-2-(2,4-dichlorophenoxy)phenol] is an antiseptic which is used in soap,
toothpaste, cosmetics etc. Sulfanilamide [IUPAC name: 4-aminobenzenesulfonamide] is
used in the treatment of vaginal infections. It reduces vaginal burning and itching.

Antihistamine drugs acts to reduce the activity of histamjne receptors and to treat
allergies. Diphenhydramine Hydrochloride [IUPAC name: 2-benzhydryloxy-N,Ndimethylethanamine; hydrochloride] or Diphenhydramine is used in the treatment of
common cold, allergy, hay fever etc.

1.4. Review of Previous Researches

There are several common methods to degrade the CECs such as electrochemical
oxidation, advanced oxidation (Fenton, cavitation, radiation etc.) and biological
degradation (MBBR, ASR, MBR etc.) [11], [37], [38]. Different researchers followed
different methods to degrade CEC compounds. In this work, electrochemical method has
been applied to observe the degradation.
In advanced oxidation processes (AOP), hydroxyl radical is produced. This radical acts
as a oxidant to degrade CEC. Several researches showed that AOP has very high
degradation efficiency (mostly over 90%) [39]–[46]. But there are also some disadvantages
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of these processes. In Fenton process, large amount of byproduct sludge is produced
through the process [39], [44]. On the other hand, cavitation or radiation processes are
expensive. Biological degradation is also an effective method to degrade CEC from
wastewater. In this method, biological organisms i.e. bacteria, fungi etc. are used in
different ways. Moving bed biofilm reactor (MBBR) uses biofilm carriers which are kept
moving in reactor with aerobic condition. Membrane bioreactor (MBR) was used in
parallel with wastewater treatment plant in different researches [47], [48]. The results
showed that this method cannot fully degrade for all types of CEC. Some pharmaceuticals
can be removed almost completely and some other are instead more recalcitrant and
difficult to degrade [47]–[49]. Researchers found that naproxen was removed 40-55%
using biological treatment [50]. In comparison with these processes, electrochemical
oxidation is the better because this is inexpensive and no byproduct sludge is produced
electrochemically. Also, the biological methods may take a long time to degrade CEC at a
desired level whereas the electrochemical degradation method might be quite faster.
Electrochemical oxidation is also a common method to degrade pharmaceuticals.
Different researchers used different electrodes such as porous Ti, boron doped diamond
[51], Ti/Pt/PbO2 [52], glassy carbon electrodes modified with poly(4-aminobenzoic acid)
[53], platinum nanoparticles coated FTO glass [54], ZnO nanoparticles and multiwalled
carbon nanotubes modified carbon paste electrode [55], modified reticulated vitreous
carbon electrodes with TiO2and CuO/TiO2/Al2O3 [46], graphite-poly vinyl chloride (PVC)
composite electrode [56], Nafion–Gr modified glassy carbon electrode [57], multi-walled
carbon nanotubes-epoxy composite electrode [58], etc. to increase the oxidation efficiency.
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L. Yang et al. showed that acetaminophen has been degraded more than 95% in 80 min
using TiO2 loading as photocatalysis [59]. Researchers found that conductive diamond
electrochemical oxidation (CDEO) technology can efficiently and possibly completely
degrade caffeine even at very low concentration [60]. It has also been found that with the
increase of the applied voltage, the removal efficiency of caffeine increases very
significantly and chloride media is better for its removal [56]. According to the
experimental result of S. Motoc et al., Ibuprofen can be degraded by applying potential at
1.2 and 1.75V vs. Ag/AgCl using multi-walled carbon nanotubes-epoxy (MWCNT) and
silver-modified zeolite-multi-walled carbon nanotubes-epoxy (AgZMWCNT) composites
electrodes [58]. Xiang Li et al. showed that ibuprofen could be completely degraded in 515min using the electro-peroxone process [61].

In this work, we used electrochemical oxidation process to degrade three analgesic
drugs i.e. Acetaminophen, Ibuprofen, Naproxen Sodium and one CNS stimulant drugs i.e.
Caffeine. Particularly, we identified the oxidation peaks of those CECs of interests at
different operating conditions i.e. concentration and pH. We applied electrical potential to
the solution containing CEC using different methods i.e. cyclic voltammetry (CV),
chronoamperometry to determine the applicability of this method.
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CHAPTER 2 EXPERIMENTAL METHODS

2.1. Reagents and Materials
Carbon fiber paper was supplied by Fuel Cell Store, USA. Acetaminophen,
Ibuprofen, Naproxen Sodium and Caffeine were obtained from Sigma-Aldrich . The
structural formulas of the pharmaceuticals are shown in Figure 1 and Figure 2. Gradient
grade Methanol (OmniSolv MX0488) and water (OmniSolv WX0004) were used to
prepare the solutions and to wash the equipments. KH2PO4, K2HPO4, NaCl, KCl,
Na2HPO4, NaH2PO4 were supplied by EMD Chemicals Incorporation. In order to
control the pH in buffer solution, KOH or H3PO4 was used which were also supplied
by EMD Chemicals Incorporation.

Figure 1. Chemical structures of the analgesic and CNS stimulant pharmaceuticals
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Figure 2. Chemical structures of the antibiotic and antihistamine pharmaceuticals [62]–
[65]

2.2. Sample Preparation
Sample solutions of the pharmaceuticals were prepared by adding them into the mixture
(approx. 50-50%V) of methanol and HPLC grade water. The concentration was 10mM for
each of the stock solutions. The prepared solutions were kept in dark and closed plastic test
tube to avoid undesired change in concentration.

As a reagent, potassium phosphate buffer (K-PB) solution (0.1M) was prepared at pH
4.5, 6.0, 7.5 and 9.0 using KH2PO4 and K2HPO4 in proper ratio. As the supporting
10

electrolyte, 0.1M KCl was added in the phosphate buffer solution. K2HPO4, H2SO4,
NaCl/KCl were used to prepare the buffer solution of pH 1.0, 3.0. And, for the preparation
of buffer solutions of pH 11.0, 13.8, Na2HPO4/NaH2PO4.H2O, NaOH, NaCl were used.

2.3. Experimental Set up
Pyrex 100mL bottle with screw cap was used as the electrochemical oxidation reactor.
In order to measure cyclic voltammetry (CV) and chronoamperometry, VersaSTAT MC
potentiostat (Princeton Applied Research) was used in a three electrode configuration
(working electrode, counter electrode and reference electrode). In our experiment, carbon
fiber paper with micro-porous layer coating, titanium wire and Ag/AgCl 3M KCl (+210
mV vs SHE) were used as the working electrode, counter electrode and the reference
electrode respectively. Four small holes were created in the cap in order to accommodate
working, counter and reference electrode and a small tube for flushing nitrogen into the
solution. The size of the working electrode (WE) or carbon fiber paper for each experiment
was the same (2×5 cm). The carbon fiber paper was connected with the connecting copper
wire in which epoxy glue was used to isolate the connection and avoid cupper corrosion in
the liquid solution. The pH value was measured using pH meter (Omega PHB-600R). The
chemicals and pharmaceuticals were weighed in Semi-Micro Analytical Balance (Ohaus
DV215CD-US) to prepare buffer solutions and sample solutions respectively.

2.4. Experimental Procedures and description
100 mL of buffer solution was taken into the Pyrex bottle. The working electrode,
counter electrode and reference electrode were placed into the solution and connected with
11

the VersaSTAT MC potentiostat. In order to avoid unwanted reaction or interaction with
oxygen, the liquid solution was flushed with nitrogen for at least 20 minutes before starting
the experiment.

2.4.1. Cyclic Voltammetry
CV was performed at each different concentration of the pharmaceuticals to
identify the oxidation peak of the pharmaceutical of interest. CV was performed in the
range between 0V to 1.8V (vs Ag/AgCl) at 100mVs-1. Pharmaceuticals were added from
the sample solution by definite known concentrations in the buffer solution. The CV
experiments were run at pH 1.0, 3.0, 4.5, 6.0, 7.5, 9.0, 11.0, 13.8.

2.4.2. Chronoamperometry
Once the oxidation peak was determined from the CVs, chronoamperometry
experiments were run at a potential slightly higher than the oxidation peak to guarantee
that degradation was taking place. The pharmaceuticals of interest were added from the
stock solution every 5 minutes to observe the variation of current at a fixed potential. The
variation of current in function of the pharmaceuticals concentration allowed to draw
concentration-response graphs simulating a non-selective biosensor for pharmaceuticals
detection. The chronoamperometry experiments were done for the pharmaceuticals at pH
6.0, pH 7.5 and pH 9.0. All experiments were performed at room temperature (25℃).
Before each experiments, the working electrode was soaked in the buffer solution for 1-2
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hours to increase the interaction between liquid and solid and diminish the electrode
hydrophobicity.

2.4.3. High-Performance Liquid Chromatography (HPLC)

High Performance Liquid Chromatography (HPLC) Agilent 1100 series was used
for detecting the concentration of the pharmaceuticals in the samples. The overall HPLC
system was equipped by: i) a degasser, ii) a pump, iii) an auto-sampler, and iv) UV-vis
detector. Fixed wavelength (210 nm) was used for detection. Waters Xterra MS-C18 15mm
column was used during the experiments and a thermostat kept the temperature of the
column stable at 28°C.

Ibuprofen, Triclosan, Sulfanilamide and Caffeine were purchased from Sigma
Aldrich. The pharmaceuticals were dissolved into stock solution composed of HPLC grade
50%:50% methanol:water. Then the stock solutions were added in the 0.1M potassium
buffer solution to make the concentration as 100 µM. Chronoamperometry experiments
were conducted at the potential higher than the oxidation potential. The samples were taken
during the chronoamperometry experiment after 5, 10, 20, 30, 45, 60 and 90 minutes. The
sample collected was 0.5 mL and was mixed with 0.5 mL of methanol.
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Samples were run into the HPLC following different methods. The first method
was used for Ibuprofen, Naproxen Sodium and Triclosan and it was based on an isocratic
flow of 0.2 mLmin-1 with a mixture ratio of 80% acetonitrile and methanol (50% each) and
20% water with 0.1% TFA. The duration of the first method was 30 minutes. The second
method instead was used for Sulfanilamide and Caffeine and it was based on an isocratic
flow of 0.2 mLmin-1 with a mixture ratio of 60% methanol and 40% water. The duration of
the first method was 25 minutes. Water, methanol and acetonitrile were HPLC graded.
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CHAPTER 3 RESULTS AND DISCUSSION

3.1. Effect of CEC concentration on electrochemical oxidation

The oxidation peak in the CV experiment indicates the electrochemical oxidation of
the pharmaceuticals. The pharmaceuticals were investigated at the range between 1 to 500
μM. CVs were initially run on blank solutions based on the buffer solution (without adding
any pharmaceuticals) within the applied potential range of 0 to 1.8V (vs Ag/AgCl). No
oxidation peak was detected in the absence of pharmaceuticals. But, the current increased
after 1-1.25V (vs Ag/AgCl) probably because the oxygen evolution reaction (OER) was
occurring. After then the pharmaceuticals were added gradually in the buffer solution and
CV was run each time after the addition. In Figure 3, the cyclic voltammetry behavior has
been shown for Acetaminophen at pH 6.0. The CVs related to other pharmaceuticals at pH
6.0, 7.5 and 9.0 are instead presented in the supporting information.
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Figure 3. Cyclic voltammogram for Acetaminophen at the concentration of (a) 0μM, 1μM,
2μM, 5μM, 10 μM and (b) 0μM, 20μM, 50μM, 100μM, 200μM, 500μM at pH 6.0.

From this figure, it is clear that the oxidation peak gets higher with the increase of
the pharmaceutical concentration. That is because at higher concentration high amount of
the reactant (pharmaceuticals) is available to be oxidized and thus higher current is
produced which can be seen as the oxidation peak. Higher concentration also shifts the
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potential towards higher values. Acetaminophen shows the oxidation peak potential nearly
at 0.5 to 0.7V (vs Ag/AgCl) at pH 6.0. The similar experiments were done for three other
pharmaceuticals which have been shown in the supporting information. From the
experimental data, it was also observed that at pH 6.0, the oxidation peak of Naproxen
Sodium shifted from 0.97 to 1.01 V (vs Ag/AgCl). From the experiment, no oxidation peak
was detected for caffeine at pH 6.0 and 7.5 using carbon fiber paper electrode.
Distinguishable peak for Ibuprofen was detected at pH 9.0 only at very high concentration
(500 μM) investigated at 1.39 V vs Ag/AgCl. In conclusion, the lower the oxidation peak,
the easier is to breaking down the pharmaceutical and consequently their degradations.

In literature, other researchers have found the oxidation peak potential for
Acetaminophen from 0.25V to 1.05V (vs Ag/AgCl) using different electrodes at different
pH solutions [51], [53], [66]–[71]. The oxidation peak potential for Caffeine, Ibuprofen
and Naproxen has been found from 1.30V to 1.60V (vs Ag/AgCl) [71]–[76] , 1.20V to
1.75V (vs Ag/AgCl) [52], [58] and 0.85V to 1.10V (vs Ag/AgCl) [55], [77] respectively at
different pH solutions using different electrodes.

3.2. Effect of pH on electrochemical oxidation

Researchers showed that the degradation efficiency of Naproxen is better at lower pH
solution [54]. Effect of pH on the electrochemical oxidation has been studied in our work.
Particularly, three different pHs (6, 7.5 and 9) were studied and used to simulate conditions
17

of the municipal or industrial wastewater. Oxidation peaks are summarized in Table 1, 2
and 3. CVs are showed in the Supporting Information.

Table 1. Oxidation peak potential (V vs Ag/AgCl) at pH 6.0
Pharmaceuticals/

10μM

20μM

50μM

100μM

200μM

500μM

0.51 ±

0.52 ±

0.55 ±

0.58 ±

0.61 ±

0.69 ±

0.03

0.03

0.03

0.05

0.05

0.05

-

-

-

-

-

1.39 ±

Concentration
Acetaminophen

Ibuprofen

0.05
Naproxen Sodium

0.97 ±

0.97 ±

0.97 ±

0.98 ±

0.96 ±

1.01 ±

0.05

0.05

0.05

0.05

0.05

0.05

Caffeine

-

-

-

-

-

-

Erythromycin H.

-

-

-

1.05 ±

1.05 ±

1.19 ±

0.03

0.03

0.03

Triclosan

Sulfanilamide

Diphenhydramine H.

-

0.79 ±

0.89 ±

0.93 ±

0.96 ±

1.03 ±

0.03

0.05

0.05

0.05

0.05

1.06 ±

1.09 ±

1.09 ±

1.08 ±

1.09 ±

1.11 ±

0.03

0.03

0.03

0.03

0.05

0.05

0.99 ±

1.00 ±

1.02 ±

1.04 ±

1.12 ±

1.22 ±

0.05

0.05

0.05

0.05

0.05

0.05
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Table 2. Oxidation peak potential (V vs Ag/AgCl) at pH 7.5
Pharmaceuticals/

10μM

20μM

50μM

100μM

200μM

500μM

0.49 ±

0.52 ±

0.56 ±

0.60 ±

0.63 ±

0.72 ±

0.03

0.03

0.03

0.05

0.05

0.05

-

-

-

-

-

1.38 ±

Concentration
Acetaminophen

Ibuprofen

0.05
Naproxen Sodium

0.96 ±

0.95 ±

0.99 ±

0.99 ±

1.01 ±

0.99 ±

0.05

0.05

0.05

0.05

0.05

0.05

Caffeine

-

-

-

-

-

-

Erythromycin H.

-

-

-

-

1.04 ±

1.1 ±

0.02

0.03

Triclosan

Sulfanilamide

Diphenhydramine H.

-

0.67 ±

0.71 ±

0.72 ±

0.71 ±

0.75 ±

0.03

0.05

0.05

0.05

0.05

0.93 ±

0.97 ±

0.98 ±

1.01 ±

1.03 ±

1.08 ±

0.03

0.03

0.03

0.03

0.05

0.05

-

0.85 ±

0.92 ±

1.03 ±

0.98 ±

1.04 ±

0.05

0.05

0.05

0.05

0.05
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Table 3. Oxidation peak potential (V vs Ag/AgCl) at pH 9.0
Pharmaceuticals/

10μM

20μM

50μM

100μM

200μM

500μM

0.34 ±

0.35 ±

0.34 ±

0.36 ±

0.38 ±

0.44 ±

0.03

0.03

0.03

0.05

0.05

0.05

-

-

-

-

-

1.37 ±

Concentration
Acetaminophen

Ibuprofen

0.05
Naproxen Sodium

Caffeine

0.94 ±

0.95 ±

0.96 ±

0.96 ±

0.96 ±

0.96 ±

0.05

0.05

0.05

0.05

0.05

0.05

1.44 ±

1.41 ±

1.43 ±

-

1.55 ±

-

0.05

0.05

0.05

-

-

-

Erythromycin H.

Triclosan

Sulfanilamide

0.05
0.91 ±

0.91 ±

0.92 ±

0.03

0.03

0.03

0.63 ±

0.64 ±

0.62 ±

0.61 ±

0.61 ±

0.58 ±

0.03

0.03

0.03

0.05

0.05

0.05

0.86 ±

0.87 ±

0.87 ±

0.92 ±

0.94 ±

0.99 ±

0.03

0.03

0.03

0.03

0.05

0.05

0.79 ±

0.83 ±

0.89 ±

0.96 ±

1.04 ±

0.05

0.05

0.05

0.05

0.05

Diphenhydramine H.
-
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In Figure 4, the voltammograms of the pharmaceuticals have been shown at
different pHs (6, 7.5 and 9) at a fixed concentration of 10 μM for Caffeine, 50 μM for
Naproxen Sodium, 100 μM for Acetaminophen and 500 μM for Ibuprofen. The results
showed that Acetaminophen and Naproxen Sodium have higher oxidation current and peak
potential in buffer solution of pH 7.5 than pH 6.0 and 9.0. Caffeine does not show oxidation
peak in the buffer solution of pH 6.0 and 7.5 using carbon fiber paper electrode probably
because the oxidation reaction takes place in the window in which oxygen evolution
reaction(OER) occurs and most likely is hindered by the OER peak itself. In literature it
has been showed that caffeine has an oxidation peak at 1.35-1.45V vs SCE at pH2.0 using
Nafion–Gr modified glassy carbon electrode [57].

At pH 9.0, Naproxen Sodium and Acetaminophen shows the lowest oxidation
current, whereas at pH 7.5 it shows the highest oxidation current as shown in Fig. 4b and
Fig. 4c. Ibuprofen shows the lowest oxidation current at pH 6.0 and the highest oxidation
current at pH 9.0. Ibuprofen shows oxidation peak only at very high concentration (500μM)
using carbon fiber paper electrode. From Figure 4d, it is clear that oxidation current or
oxidation peak potential does not vary substantially with the change of pH for Ibuprofen,
but still the highest oxidation peak potential is shown at pH 6.0 which is different from
Acetaminophen and Naproxen Sodium. It might be speculated that, as for caffeine, the
oxidation peak occurs at high potentials in which OER occurs.
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Figure 4. Cyclic voltammogram showing the Effect of pH on electrochemical oxidation of
a) Caffeine (10μM) b) Naproxen Sodium (50μM) c) Acetaminophen (100μM) d) Ibuprofen
(500μM)

In Figure 5, the voltammograms of the pharmaceuticals have been shown at
different pHs (6, 7.5 and 9) at a fixed concentration of 200 μM. It has been observed that
pH 6.0 showed higher oxidation peak potential than pH 7.5 and 9.0. Also, pH 9.0 buffer
22

solution showed the lowest oxidation peak potential among them. Thus we can conclude
that oxidation peak potential is not linearly related to pH in the circumneutral pH range.
The following figures depict the effect of circumneutral pH on the oxidation peak potential
and current.

Figure 5. Effect of pH on electrochemical oxidation of a) Erythromycin Hydrate b)
Triclosan c) Sulfanilamide d) Diphenhydramine Hydrochloride at the fixed concentration
of 200 μM.
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To further investigate the relation between the oxidation peak potential and pH,
CVs were run in the buffer solutions of different pH from 1.0 to 13.7 with concentration
of 100 μM. In agreement with the data presented above, Ibuprofen and Caffeine had
oxidation peak potential above 1.25 V vs Ag/AgCl and consequently the peak might be
hindered by the OER and thus the oxidation peak was not clear. That is why this study was
not performed on them. Also, Erythromycin Hydrate and Diphenhydramine Hydrochloride
did not show clear oxidation in the full range from pH of 1.0 to 13.7. Thus the experimental
results of the change of oxidation peak potential (V vs Ag/AgCl) with pH for
Acetaminophen, Naproxen Sodium, Triclosan and Sulfanilamide have been shown in
Figure 6 and Figure 7.

Figure 6. The change in oxidation peak potential of Acetaminophen and Naproxen Sodium
with pH in the circumneutral region at the fixed concentration of 100µM.
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Concerning Acetaminophen, it can be noticed that the oxidation peak potential
decreases linearly with the increase of pH from acidic to basic mediium. But in the neutral
pH region, the oxidation peak potential shows fluctuation in the oxidation peak potential
as shown in Figure 6. In the case of Naproxen Sodium, the oxidation peak potential
decreases with pH in the acidic medium following a non-linear trend. In the experiments,
Naproxen Sodium did not show any oxidation peak potential in pH 13.7 using carbon fiber
paper electrode, so the correlation between oxidation peak potential and pH for Naproxen
Sodium cannot be established in the basic medium. But, in the neutral pH medium, it also
shows fluctuation in the oxidation peak potential with the change of pH. Single CV
regarding each pH are presented in the Supporting information.

Figure 7. The change in oxidation peak potential of Triclosan and Sulfanilamide with pH
at the fixed concentration of 200µM.
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It is also observed that oxidation peak potentials for Triclosan and Sulfanilamide were
not absolutely linear with pH. There was a sudden increase of oxidation peak potential at
pH 5 and pH 11. But in overall, it is clear that the oxidation potential decreases with pH.

3.3. Cumulative oxidation peaks with simultaneous presence of several
pharmaceuticals in the electrolyte

In real conditions, different pharmaceuticals may exist together in the wastewater. To
achieve the similar condition, the four pharmaceuticals from the analgesic and CNS
stimulant category were mixed together in the same proportion and added in the buffer
solution of pH 6.0, 7.5 and 9.0 at different concentrations (each pharmaceuticals of 100μM,
150μM and 200μM). Then, CVs were run to detect the oxidation peaks. CVs showed that
the solution mixture of four pharmaceuticals had only two clear oxidation peak potentials
at 0.6 and 1.1V respectively at pH 6.0 as shown in Figure 8.
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Figure 8. Cyclic voltammogram of the mixed solution of the analgesic pharmaceuticals at
different concentration at pH 6.0.

These two oxidation peak potentials resemble with Acetaminophen and Naproxen
Sodium as shown in Figure 4 or Table 1. Caffeine and Ibuprofen did not show any
detectable oxidation peak at those concentrations at pH6.0. in this mixed solution probably
because that was hindered or overlapped by the OER window. The results from pH 7.5 and
9.0 have been included in appendix.

The similar experiments have also been done for the four antibiotic and
antihistamine pharmaceuticals which is shown in Figure 9. From the figure, it can be seen
that CV does not show four distinct oxidation peaks, rather it shows a single oxidation peak
at 1.0-1.15 V. The probable reason is that the oxidation peak for the pharmaceuticals are
close to each other. That is why the four different oxidation are overlapping at near to 1.0
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V. Since, they are showing a clear oxidation peak, so it can be concluded that
electrochemical degradation is applicable in the mixture of multiple pharmaceuticals or
CEC.

Figure 9. Cyclic voltammetry of the mixed solution of the pharmaceuticals at different
concentration at pH 6.0.
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3.4. Determination of Concentration using Chronoamperometry Data

In the chronoamperometry experiments, the variation of current was observed with the
change of the concentration of the pharmaceuticals at a constant applied potential. The
fixed potential was chosen a higher value than the oxidation peak potential of the
pharmaceuticals. Concentration and current response relationships have been built from
the experimental data and this relation can be used as non-selective biosensors for detecting
pharmaceuticals in aqueous media. Considering that Ibuprofen and Caffeine have high
oxidation peak potential within the range in which OER occurs, these two pharmaceuticals
were then excluded from chronoamperometry experiment.

At pH 7.5 (Figure 11), Naproxen Sodium has higher background current compared to
Acetaminophen probably due to the higher applied potential. The measured current has
been shown. Current increased with the increase of the pharmaceutical concentration in
buffer solution (from 0 to 50 µM every 5 minutes). The interval time between the additions
of the pharmaceutical was kept relatively low (5 min) in order to evaluate the change in
current due to the pharmaceutical concentration and to avoid the degradation effect.
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Figure 10. Chronoamperometry Data for Acetaminophen and Naproxen Sodium at pH 7.5

Current produced vs concentration linear relationships are here presented for
Acetaminophen (Figure 12.a) and Naproxen Sodium (Figure 12.b) at pH 6.0, 7.5 and 9.0.
Current signal was determined by subtracting the background current from the actual
current. From the figure, pH 9.0 has higher slope than others which indicates that
Acetaminophen and Naproxen Sodium can be easily ionized in alkaline medium. On the
other hand, the lowest slope is found in the neutral (pH 7.5) medium.
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Figure 11. Current versus concentration linear trend for a) Acetaminophen b) Naproxen
Sodium at pH 6, 7.5 and 9.

In the chronoamperometry experiments, the variation of current was observed with
the change of the concentration of the pharmaceuticals at a constant applied potential. The
fixed potential was chosen a higher value than the oxidation peak potential of the
pharmaceuticals. Concentration and current response relationships have been built from
the experimental data. Chronoamperometry graphs have been shown in Figure 11 and
Figure 12. The current increased with the increase of the pharmaceutical concentration in
buffer solution (from 0 to 50 µM every 5 minutes). The interval time for the pharmaceutical
addition was kept relatively low (5 min) in order to evaluate the change in current due to
the pharmaceutical concentration and to avoid the degradation effect.
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Figure 12. Chronoamperometry Data for Diphenhydramine Hydrochloride (1.10V),
Erythromycin Hydrate (1.05V), Triclosan (0.95V) and Sulfanilamide (1.02V) and at pH
7.5.

From the Figure 12, it is clear that the increase of current is not the same for the
different pharmaceuticals with the addition of equal moles. The current is increased by
approximately 20µA and 5µA for the addition of 5µM of Erythromycin Hydrate and
Triclosan respectively. This indicates that Erythromycin Hydrate can be easily ionized in
the aqueous solution. Using the data from chronoamperometry experiment, non-selective
biosensors can be developed for detecting pharmaceuticals in aqueous media.
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Figure 13. Change of current with CEC concentration at different pH for a) Erythromycin
Hydrate (1.05V) b) Triclosan (0.85V) c) Sulfanilamide (1.06V, 1.02V, 1.0V) d)
Diphenhydramine Hydrochloride (1.10V)

The linear relationship between the produced current and concentration for the
pharmaceuticals are presented for Erythromycin hydrate, Triclosan, Sulfanilamide, and
Diphenhydramine in Figure 13. But it was not linear for Triclosan at pH 6.0 and
Sulfanilamide at pH 9.0. From this figure, we can also get the idea of the effect of pH on
the produced current for the presence of the pharmaceuticals. Sulfanilamide and
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Diphenhydramine Hydrochloride show the similar effect of pH where the slope is high at
pH 9 (initially) and low at 7.5. This indicates that at pH 9, Sulfanilamide and
Diphenhydramine Hydrochloride can be ionized more than at pH 6 and 7.5. But, for
Erythromycin Hydrate the slope is higher at pH 7.5 and lower at pH 6. For Triclosan, the
higher slope is found at pH 6 (initially), but after increasing concentration at 30 µM current
signal became stable and does not increase anymore. The lower slope for Triclosan is found
at pH 9.
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3.5. Determination of electrochemical degradation rate using HPLC Data

The pharmaceutical solutions were put under an applied potential higher than the
oxidation potential, so the solution should have gone under the oxidation as well as
degradation. To verify the degradation of the pharmaceuticals, HPLC experiments were
performed. Since, HPLC experiments cannot tell the real concentration of any elements in
the solution, rather it can only give the peak and the area which is dependent on the
concentration. So firstly calibration curves were prepared from the known concentration of
the pharmaceuticals. Calibration curves for Sulfanilamide and Triclosan are shown in
Figure 14 & Figure 16.

Figure 14. a) Chromatogram for Standard solution and b) Calibration Curve for
Sulfanilamide.
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Figure 15. a) Chromatogram for the samples taken at different time after applying potential
(1.1V) in pH 7.5 potassium buffer solution containing sulfanilamide b) Enlarged
Chromatogram at region of interest c) Degradation curve for Sulfanilamide.
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From Figure 14, we got a relationship between the area of the chromatograph and the
concentration of sulfanilamide. In Figure 15, chromatogram for the samples taken at
different time after applying potential has been shown for sulfanilamide. The correlation
that we have found from the calibration curve has been used to determine the concentration
of sulfanilamide in the samples. From the degradation curve in Figure 15 c, we can
determine the 1st order reaction constant for Sulfanilamide. k = 0.0039 min-1 and half
lifetime, t1/2 = 177.7 min

In Figure 16, chromatogram and the calibration curve for Triclosan have been shown.
Using the correlation from the calibration curve, the degradation curve has been developed,
which is shown in Figure 17.

Figure 16: a) Chromatogram for Standard solution and b) Calibration Curve for
Triclosan.
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Figure 17: a) Chromatogram for the samples taken at different time after applying potential
(0.85V) in pH 7.5 potassium buffer solution containing Triclosan b) Enlarged
Chromatogram at region of interest c) Degradation curve for Triclosan.
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From the degradation curve, 1st order reaction constant for Triclosan. k = 0.0148 min-1 and
half lifetime, t1/2 = 46.82 min were determined.
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CHAPTER 4 CONCLUSION

In this research, 8 different pharmaceuticals have been studied for the
electrochemical degradation. To determine the oxidation potential, CV experiments have
been performed using ‘carbon fiber paper’ as working electrode. From the experiments,
Analgesic and CNS stimulant pharmaceuticals i.e. Acetaminophen, Ibuprofen, Naproxen
Sodium, Caffeine showed oxidation peak at 0.34-0.79V, 1.37- 1.39V, 0.94-1.01V, 1.441.55V respectively at different pH and concentrations.

Antibiotic and antihistamine pharmaceuticals i.e. Erythromycin Hydrate, Triclosan,
Sulfanilamide, Diphenhydramine Hydrochloride also showed oxidation peak at 0.911.19V, 0.58-1.03V, 0.86-1.11V, 0.79-1.22V respectively at different pH and
concentrations. Sensor curves have been developed for 6 pharmaceuticals which is shown
in Figure 11 and Figure 13. Electrochemical degradation was measured using HPLC
instrument. The 1st order reaction constants are 0.0039 min-1 and 0.0148 min-1 for
sulfanilamide and Triclosan respectively.
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4.1. Limitations

The 1st order reaction rate constants were found only for Triclosan and Sulfanilamide.
Ibuprofen and caffeine have very high oxidation potential over the OER window. For
which the samples were not prepared for these two pharmaceuticals. For other
pharmaceuticals, proper method of separation was not established.

The derivatives which are being produced after degrading the pharmaceuticals have not
been analyzed. If the derivatives themselves are harmful, then the degradation by this way
cannot be followed. But generally, the derivatives from the pharmaceuticals are more polar
and water soluble which should have a reduced pharmacological activity compared to the
original compound.

At every pH, oxidation potentials could not be found for the pharmaceuticals. Also, the
oxidation potential for some pharmaceuticals are very high which cannot be applied in real
conditions. Further analysis is required to find out lower oxidation potential or to find in other
pH using different electrodes.
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4.2. Future Work
Different other electrodes such as activated glassy carbon electrode, boron doped
diamond, Ti etc. can be studied for the better result in some cases where the oxidation
potential could not be found using carbon fiber paper electrode. Catalyst can also be
applied on the electrode to observe better performance. The derivatives that are
produced from the electrochemical oxidation should also be studied whether those are
harmless or not. Since, there are many other major pharmaceuticals present in the
aquatic environment, those compounds should also be studied in the similar way.
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CHAPTER 5 APPENDICES
Appendix A

Cyclic Voltammetry Data

Figure A. 1. Cyclic voltammogram for Acetaminophen at pH7.5 at different concentration.
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Figure A. 2. Cyclic voltammogram for Acetaminophen at pH9.0 at different concentration.
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Figure A. 3. Cyclic voltammogram for Caffeine at pH6.0 at different concentration.
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Figure A. 4. Cyclic voltammogram for Caffeine at pH7.5 at different concentration.
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Figure A. 5. Cyclic voltammogram for Caffeine at pH9.0 at different concentration.
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Figure A. 6. Cyclic voltammogram for Naproxen Sodium at pH6.0 at different
concentration.
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Figure A. 7. Cyclic voltammogram for Naproxen Sodium at pH7.5 at different
concentration.
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Figure A. 8. Cyclic voltammogram for Naproxen Sodium at pH9.0 at different
concentration.
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Figure A. 9. Cyclic voltammogram for Ibuprofen at pH6.0 at different concentration.
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Figure A. 10. Cyclic voltammogram for Ibuprofen at pH7.5 at different concentration.
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Figure A. 11. Cyclic voltammogram for Ibuprofen at pH9.0 at different concentration.
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Antibiotic + Antihistamine:

Figure A. 12. Cyclic voltammogram of Erythromycin Hydrate at pH6.0 at different
concentration.
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Figure A. 13. Cyclic voltammogram of Erythromycin Hydrate at pH7.5 at different
concentration.
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Figure A. 14. Cyclic voltammogram of Erythromycin Hydrate at pH9.0 at different
concentration.
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Figure A. 15. Cyclic voltammogram of Triclosan at pH6.0 at different concentration.
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Figure A. 16. Cyclic voltammogram of Triclosan at pH7.5 at different concentration.
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Figure A. 17. Cyclic voltammogram of Triclosan at pH9.0 at different concentration.

59

Figure A. 18. Cyclic voltammogram of Diphenhydramine Hydrochloride at pH6.0 at
different concentration.
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Figure A. 19. Cyclic voltammogram of Diphenhydramine Hydrochloride at pH7.5 at
different concentration.
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Figure A. 20. Cyclic voltammogram of Diphenhydramine Hydrochloride at pH9.0 at
different concentration.
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Figure A. 21. Cyclic voltammogram of Sulfanilamide at pH6.0 at different concentration.
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Figure A. 22. Cyclic voltammogram of Sulfanilamide at pH7.5 at different concentration.
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Figure A. 23. Cyclic voltammogram of Sulfanilamide at pH9.0 at different concentration.
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Appendix B
Chronoamperometry Data

Figure B. 1. Chronoamperometry of Acetaminophen at (a) pH6.0 at applied potential 0.65V
(b) pH7.5 at applied potential 0.65V (c) pH9.0 at applied potential 0.5V.
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Figure B. 2. Chronoamperometry of Naproxen Sodium at applied potential 1.0 V at (a)
pH6.0 (b) pH7.5 (c) pH9.0
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Figure B. 3. Chronoamperometry of Erythromycin Hydrate at Potential 1.05 V at (a) pH6.0
(b) pH7.5 (c) pH9.0
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Figure B. 4. Chronoamperometry of Triclosan at Potential 0.85 V at (a) pH6.0 (b) pH7.5
(c) pH9.0
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Figure B. 5. Chronoamperometry of Diphenhydramine Hydrochloride at Potential 1.10V
at (a) pH6.0 (b) pH7.5 (c) pH9.0
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Figure B. 6. Chronoamperometry of Sulfanilmide at (a) pH6.0 at 1.06V (b) pH7.5 at 1.02V
(c) pH9.0 at 1.0V
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